Ambrx Biopharma Long Term Debt 2020-2021 | AMAM

Ambrx Biopharma long term debt from 2020 to 2021. Long term debt can be defined as the sum of all long term debt fields.
Ambrx Biopharma Annual Long Term Debt
(Millions of US $)
2021 $
2020 $
2019 $
Ambrx Biopharma Quarterly Long Term Debt
(Millions of US $)
2021-12-31
2020-12-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.149B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00